Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety
NCT07174947Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluoxetine in hepatobiliary cancers (HBC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Started Oct 2025; status: recruiting.
02
Drugs
fluoxetine
03
Conditions
hepatobiliary cancers (HBC)
Beyond the preview
Go deeper on NCT07174947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174947.